Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction Robert A. Nathan, MDa, Jonathan A.

Slides:

Advertisements

Similar presentations

Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane- beclomethasone extrafine inhalation aerosol), in asthma Jennifer.

Advertisements

W.Travis Cain, MDa, Greg Cable, PhDb, John J. Oppenheimer, MDc

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

House dust mite avoidance measures improve peak flow and symptoms in patients with allergy but without asthma: A possible delay in the manifestation of.

Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis Fuad M. Baroody, MD, David Brown, MD,

Double-blind placebo-controlled study of the efficacy of oral terfenadine in the treatment of chronic fatigue syndrome Paul Steinberg, MDa, Bruce E.

Salmeterol resolves airway obstruction but does not possess anti-eosinophil efficacy in newly diagnosed asthma: A randomized, double-blind, parallel group.

Diane J. Pincus, MD, Stanley J. Szefler, MD, Lynn M

F.Estelle R. Simons, MDa, Bruce M. Prenner, MDb, Albert Finn, MDc

Ulrich Wahn, MDa. ‡, Eli O. Meltzer, MDb. ‡, Albert F. Finn, MDc

A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children Mark Boguniewicz, MDa, Virginia C. Fiedler,

Richard L. ZuWallack, MD a,b, James P

Protective effect of inhaled budesonide against unlimited airway narrowing to methacholine in atopic patients with asthma Patrick Booms, MSca, David.

Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis Paul H. Ratner,

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Badrul A. Chowdhury, MD, PhD

Comparison of the effects of terfenadine with fexofenadine on nasal provocation tests with allergen Maria-Helena Terrien, MD, François Rahm, MD, Jean-Marc.

Multicenter, double-blind, placebo-controlled, multiple-challenge evaluation of reported reactions to monosodium glutamate Raif S. Geha, MDa, Alexa Beiser,

Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis James.

As-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis Albert Jen, MD, Fuad Baroody, MD, Marcy de Tineo,

Harold B. Kaiser, MDa, Steven R. Findlay, MD†, John W

Elinor Simons, MDa, William M

Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis Fuad M. Baroody, MD, David Brown, MD,

Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: A randomized clinical trial William Busse, MDa,

The impact of allergic rhinitis on bronchial asthma

Inhaled fluticasone propionate delivered by means of two different multidose powder inhalers is effective and safe in a large pediatric population with.

Low-dose levalbuterol in children with asthma: Safety and efficacy in comparison with placebo and racemic albuterol Henry Milgrom, MDa, David P. Skoner,

Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroid–dependent, persistent asthma Gail.

Paul M. O’Byrne, MB, FRCPI, FRCP(C)a, Soren Pedersen, MD, PhDb

A dose-ranging study of the efficacy and safety of azelastine nasal spray in the treatment of seasonal allergic rhinitis with an acute model John M.

Physician-targeted program on inhaled therapy for childhood asthma

Correlation between alcohol-induced asthma and acetaldehyde dehydrogenase-2 genotype Atsuko Takao, MDa, Terufumi Shimoda, MDa, Shigeru Kohno, MDa, Sadahiro.

James P. Kemp, MDa, David A. Cook, MDb, Gary A

Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis Sakari Reitamo, MDa,

Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: A randomized, double-blind, placebo-controlled.

Wine-induced asthma: A placebo-controlled assessment of its pathogenesis Hassan Vally, BSc (Hons), Amanda Carr, BAppSc, Jacque El-Saleh, RN, Philip Thompson,

Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with.

Efficacy of nebulized budesonide in treatment of severe infantile asthma: A double-blind study Jacques de Blic, MDa, Christophe Delacourt, MDa, Muriel.

Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma William.

Salmeterol resolves airway obstruction but does not possess anti-eosinophil efficacy in newly diagnosed asthma: A randomized, double-blind, parallel group.

Exercise-induced bronchoconstriction in children: Montelukast attenuates the immediate-phase and late-phase responses Raul E. Melo, MD, Dirceu Solé,

Jack M. Becker, MDa, Anjali Arora, MDb, Richard J

F.Estelle R. Simons, MDa, Bruce M. Prenner, MDb, Albert Finn, MDc

Model for outcomes assessment of antihistamine use for seasonal allergic rhinitis Robert P. Harvey, MD, Carolyn Comer, MD, Barbara Sanders, MD, Ross Westley,

Fluticasone propionate powder administered through Diskhaler versus triamcinolone acetonide aerosol administered through metered-dose inhaler in patients.

Thomas B. Casale, MDa, I. Leonard Bernstein, MDb, William W

A comparison of multiple doses of fluticasone propionate and beclomethasone dipropionate in subjects with persistent asthma Gordon D. Raphael, MDa, Robert.

The effects of triamcinolone acetonide aqueous nasal spray on adrenocortical function in children with allergic rhinitis Anjuli S. Nayak, MDa, Mark H.

Fluticasone propionate powder: Oral corticosteroid–sparing effect and improved lung function and quality of life in patients with severe chronic asthma

Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic.

A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray

Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma Eugene R. Bleecker, MDa, Michael J. Welch, MDb,

Omalizumab improves asthma-related quality of life in patients with severe allergic asthma Albert Finn, MDa, Gary Gross, MDb, Julius van Bavel, MDc,

A randomized, double-blind trial of the effect of treatment with montelukast on bronchial hyperresponsiveness and serum eosinophilic cationic protein.

The 30th anniversary of the American Board of Allergy and Immunology: Then and now Lynn Des Prez a, Charles E. Reed, MD, Lawrence B. Schwartz, MDb, John.

Steroid-sparing effects of fluticasone propionate 100 μg and salmeterol 50 μg administered twice daily in a single product in patients previously controlled.

Leukotriene receptor antagonists in asthma therapy

Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma James P.

Studies on the relationship between the level of specific IgE antibodies and the clinical expression of allergy: I. Definition of levels distinguishing.

Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib Pär Gyllfors,

Anaphylaxis after initial ingestion of rambutan, a tropical fruit

Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane- beclomethasone extrafine inhalation aerosol), in asthma Jennifer.

Diane J. Pincus, MD, Stanley J. Szefler, MD, Lynn M

Larry C. Borish, MDa, Harold S

A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis Warner Carr, MD, Jonathan Bernstein, MD, Phil Lieberman,

Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal.

Asthma symptoms and airway hyperresponsiveness are lower during treatment with nedocromil sodium than during treatment with regular inhaled albuterol

Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: A randomized, placebo-controlled clinical trial Eli O. Meltzer, MDa,

Comparative efficacy and safety of a once-daily loratadine-pseudoephedrine combination versus its components alone and placebo in the management of seasonal.

Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma Philippe Gevaert, MD, PhD, Lien Calus, MD, Thibaut Van Zele,

Presentation transcript:

Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction Robert A. Nathan, MDa, Jonathan A. Bernstein, MDb, Leonard Bielory, MDc, Catherine M. Bonuccelli, MDd, William J. Calhoun, MDe, Stanley P. Galant, MDf, Laura A. Hanby, MSd, James P. Kemp, MDg, Jelle W. Kylstra, MDd, Anjuli S. Nayak, MDh, John P. O’Connor, PhDi, Howard J. Schwartz, MDj, D.Loren Southern, MDk, Sheldon L. Spector, MDl, Paul V. Williams, MDm Journal of Allergy and Clinical Immunology Volume 102, Issue 6, Pages 935-942 (December 1998) DOI: 10.1016/S0091-6749(98)70331-8 Copyright © 1998 Mosby, Inc. Terms and Conditions

Fig. 1 Least-squares means (repeated-measures analysis) for daytime asthma symptoms score during 13 weeks of double-blind treatment with zafirlukast or placebo. A significant treatment difference, favoring zafirlukast, was noted across the treatment period (P < .001). Journal of Allergy and Clinical Immunology 1998 102, 935-942DOI: (10.1016/S0091-6749(98)70331-8) Copyright © 1998 Mosby, Inc. Terms and Conditions

Fig. 2 Least-squares means (repeated-measures analysis) for nighttime awakenings with asthma during 13 weeks of double-blind treatment with zafirlukast or placebo. A significant treatment difference, favoring zafirlukast, was noted across the treatment period (P < .001). Journal of Allergy and Clinical Immunology 1998 102, 935-942DOI: (10.1016/S0091-6749(98)70331-8) Copyright © 1998 Mosby, Inc. Terms and Conditions

Fig. 3 Least-squares means (repeated-measures analysis) for nasal congestion score during 13 weeks of double-blind treatment with zafirlukast or placebo. A significant treatment difference, favoring zafirlukast, was noted across the treatment period (P < .001). Journal of Allergy and Clinical Immunology 1998 102, 935-942DOI: (10.1016/S0091-6749(98)70331-8) Copyright © 1998 Mosby, Inc. Terms and Conditions

Fig. 4 Least-squares means (ANCOVA) for FEV1 (L) during double-blind treatment for patients in zafirlukast or placebo groups who had a baseline FEV1 less than 65% of predicted. Asterisk (*) denotes significant treatment differences, favoring zafirlukast, at all time points, including end point (P < .01). Journal of Allergy and Clinical Immunology 1998 102, 935-942DOI: (10.1016/S0091-6749(98)70331-8) Copyright © 1998 Mosby, Inc. Terms and Conditions

Fig. 5 A, Mean change in AQLQ results from baseline to end point for the zafirlukast and placebo groups. At end point, ANCOVA showed that the zafirlukast group (nZ = 196) had significantly greater improvements from baseline in all 4 QOL domains and the overall QOL assessment score (P ≤ .018) compared with the placebo group (np = 175). Δ indicates the least-squares mean treatment difference at end point (zafirlukast minus placebo). B, Percentage of patients in zafirlukast and placebo groups with a clinically meaningful improvement at end point (≥ 0.5-unit change from baseline) in the 4 QOL domains and overall QOL assessment score (Cochran-Mantel-Haenszel Test). Compared with the placebo group, significantly more patients in the zafirlukast group had clinically meaningful improvements in all QOL domains and the overall QOL assessment score (P ≤ .037). Treatment bars are stratified to show the proportion of patients with clinically meaningful improvements of 0.5 or greater through less than 1.0 units (minimal improvement) and 1.0 units or greater (moderate improvement or better). Journal of Allergy and Clinical Immunology 1998 102, 935-942DOI: (10.1016/S0091-6749(98)70331-8) Copyright © 1998 Mosby, Inc. Terms and Conditions